Note to the Board of BLT, page-2

The matter of the vector AAV8 has always been listed in the trial protocol as an exclusion criteria.

https://clinicaltrials.gov/ct2/show/NCT01899092?term=TT-034&rank=1

Exclusion Criteria:

• Body mass index < 18.5 or > 30
• Female subjects of childbearing potential (including females with tubal ligation) or women who are pregnant or nursing
• Male subjects who are unwilling to provide the required semen samples
• Presence of nAb levels to AAV8 that abrogate AAV8 transduction

I would have thought that the clinical trial has merits going ahead because immunity would not have been such an issue, no?